Linked Life Data

18922243

Source:http://linkedlifedata.com/resource/pubmed/id/18922243

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2008-10-16
pubmed:abstractText
Anxiety disorders are highly prevalent and disabling disorders, for which selective serotonin reuptake inhibitor (SSRI) antidepressants are an effective treatment. Escitalopram is the most selective SSRI available. Beyond its well-established efficacy in depression with or without anxiety, preclinical studies have demonstrated that escitalopram has a broad spectrum of anxiolytic activity.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0013-7006
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
400-8
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].
pubmed:affiliation
Service de psychiatrie adulte et CNRS centre Emotion, groupe hospitalier de la Pitié-Salpêtrière, AP-HP, 47, boulevard de l'Hôpital, 75013 Paris, France. antoine.pelissolo@psl.aphp.fr
pubmed:publicationType
Journal Article, English Abstract, Review